Antares Pharma (ATRS) Scheduled to Post Earnings on Tuesday

Antares Pharma (NASDAQ:ATRS) will be releasing its earnings data before the market opens on Tuesday, November 6th. Analysts expect Antares Pharma to post earnings of ($0.02) per share for the quarter.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). The firm had revenue of $14.16 million during the quarter, compared to analysts’ expectations of $13.70 million. Antares Pharma had a negative net margin of 35.53% and a negative return on equity of 64.96%. On average, analysts expect Antares Pharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ:ATRS traded down $0.03 on Wednesday, hitting $3.09. The stock had a trading volume of 9,318 shares, compared to its average volume of 2,259,888. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.89 and a current ratio of 2.33. The firm has a market cap of $500.65 million, a price-to-earnings ratio of -28.64 and a beta of 0.39. Antares Pharma has a 1 year low of $1.58 and a 1 year high of $3.93.

In related news, CEO Robert F. Apple sold 43,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $3.75, for a total value of $161,250.00. Following the completion of the transaction, the chief executive officer now directly owns 1,573,562 shares of the company’s stock, valued at approximately $5,900,857.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jacques Gonella sold 49,507 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $3.09, for a total transaction of $152,976.63. Following the completion of the transaction, the director now directly owns 9,985,848 shares of the company’s stock, valued at $30,856,270.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 743,000 shares of company stock valued at $2,604,250. 12.20% of the stock is currently owned by company insiders.

Several equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, September 28th. Raymond James raised their price target on shares of Antares Pharma from $3.85 to $5.25 and gave the stock a “strong-buy” rating in a research note on Tuesday, October 2nd. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research note on Monday, October 1st. Jefferies Financial Group raised their price target on shares of Antares Pharma to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. Finally, ValuEngine upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, August 8th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Antares Pharma presently has an average rating of “Buy” and an average target price of $5.31.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: What does cost of debt say about a company’s financial health?

Earnings History for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply